Structures of α-synuclein filaments from multiple system atrophy.


Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
09 2020
Historique:
received: 05 02 2020
accepted: 22 04 2020
pubmed: 29 5 2020
medline: 22 10 2020
entrez: 29 5 2020
Statut: ppublish

Résumé

Synucleinopathies, which include multiple system atrophy (MSA), Parkinson's disease, Parkinson's disease with dementia and dementia with Lewy bodies (DLB), are human neurodegenerative diseases

Identifiants

pubmed: 32461689
doi: 10.1038/s41586-020-2317-6
pii: 10.1038/s41586-020-2317-6
pmc: PMC7116528
mid: EMS107716
doi:

Substances chimiques

alpha-Synuclein 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

464-469

Subventions

Organisme : NIA NIH HHS
ID : P30 AG010133
Pays : United States
Organisme : Medical Research Council
ID : MC_EX_MR/N027892/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UP_A025_1013
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NINDS NIH HHS
ID : U01 NS110437
Pays : United States
Organisme : Medical Research Council
ID : MC_U105184291
Pays : United Kingdom

Références

Goedert, M., Jakes, R. & Spillantini, M. G. The synucleinopathies: twenty years on. J. Parkinsons Dis. 7, S51–S69 (2017).
pubmed: 28282814 pmcid: 5345650 doi: 10.3233/JPD-179005
Spillantini, M. G. et al. α-Synuclein in Lewy bodies. Nature 388, 839–840 (1997).
pubmed: 9278044
Polymeropoulos, M. H. et al. Mutation in the α-synuclein gene identified in families with Parkinson’s disease. Science 276, 2045–2047 (1997).
pubmed: 9197268
Fitzpatrick, A. W. P. et al. Cryo-EM structures of tau filaments from Alzheimer’s disease. Nature 547, 185–190 (2017).
pubmed: 28678775 pmcid: 5552202 doi: 10.1038/nature23002
Falcon, B. et al. Structures of filaments from Pick’s disease reveal a novel tau protein fold. Nature 561, 137–140 (2018).
pubmed: 30158706 pmcid: 6204212 doi: 10.1038/s41586-018-0454-y
Falcon, B. et al. Tau filaments from multiple cases of sporadic and inherited Alzheimer’s disease adopt a common fold. Acta Neuropathol. 136, 699–708 (2018).
pubmed: 30276465 pmcid: 6208733 doi: 10.1007/s00401-018-1914-z
Falcon, B. et al. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature 568, 420–423 (2019).
pubmed: 30894745 pmcid: 6472968 doi: 10.1038/s41586-019-1026-5
Zhang, W. et al. Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer’s and Pick’s diseases. eLife 8, e43584 (2019).
pubmed: 30720432 pmcid: 6375701 doi: 10.7554/eLife.43584
Zhang, W. et al. Novel tau filament fold in corticobasal degeneration. Nature 580, 283–287 (2020).
pubmed: 32050258 pmcid: 7148158 doi: 10.1038/s41586-020-2043-0
Singleton, A. B. et al. α-Synuclein locus triplication causes Parkinson’s disease. Science 302, 841 (2003).
pubmed: 14593171 doi: 10.1126/science.1090278
Kiely, A. P. et al. α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson’s disease and multiple system atrophy? Acta Neuropathol. 125, 753–769 (2013).
pubmed: 23404372 pmcid: 3681325 doi: 10.1007/s00401-013-1096-7
Kiely, A. P. et al. Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation. Mol. Neurodegener. 10, 41 (2015).
pubmed: 26306801 pmcid: 4549856 doi: 10.1186/s13024-015-0038-3
Pasanen, P. et al. Novel α-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson’s disease-type pathology. Neurobiol. Aging 35, 2180.e1–2180. e5 (2014).
doi: 10.1016/j.neurobiolaging.2014.03.024
Nalls, M. A. et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat. Genet. 46, 989–993 (2014).
pubmed: 25064009 pmcid: 4146673 doi: 10.1038/ng.3043
Dejerine, J. & Thomas, A. L’atrophie olivo-ponto-cérébelleuse. Nouv. Iconogr. Salpêtrière 13, 330–370 (1900).
Graham, J. G. & Oppenheimer, D. R. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J. Neurol. Neurosurg. Psychiatry 32, 28–34 (1969).
pubmed: 5774131 pmcid: 493381 doi: 10.1136/jnnp.32.1.28
Quinn, N. Multiple system atrophy – the nature of the beast. J. Neurol. Neurosurg. Psychiatry 52 (suppl.), 78–89 (1989).
pmcid: 1033311 doi: 10.1136/jnnp.52.Suppl.78
Papp, M. I., Kahn, J. E. & Lantos, P. L. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy–Drager syndrome). J. Neurol. Sci. 94, 79–100 (1989).
pubmed: 2559165 doi: 10.1016/0022-510X(89)90219-0
Wakabayashi, K., Yoshimoto, M., Tsuji, S. & Takahashi, H. α-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci. Lett. 249, 180–182 (1998).
pubmed: 9682846 doi: 10.1016/S0304-3940(98)00407-8
Spillantini, M. G. et al. Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson’s disease and dementia with Lewy bodies. Neurosci. Lett. 251, 205–208 (1998).
pubmed: 9726379 doi: 10.1016/S0304-3940(98)00504-7
Tu, P. H. et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α-synuclein. Ann. Neurol. 44, 415–422 (1998).
pubmed: 9749615 doi: 10.1002/ana.410440324
Kato, S. & Nakamura, H. Cytoplasmic argyrophilic inclusions in neurons of pontine nuclei in patients with olivopontocerebellar atrophy: immunohistochemical and ultrastructural studies. Acta Neuropathol. 79, 584–594 (1990).
pubmed: 2163181 doi: 10.1007/BF00294235
Petrovic, I. N. et al. Multiple system atrophy–parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov. Disord. 27, 1186–1190 (2012).
pubmed: 22806758 doi: 10.1002/mds.25115
Davidson, W. S., Jonas, A., Clayton, D. F. & George, J. M. Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273, 9443–9449 (1998).
pubmed: 9545270 doi: 10.1074/jbc.273.16.9443
Uéda, K. et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 11282–11286 (1993).
pubmed: 8248242 doi: 10.1073/pnas.90.23.11282 pmcid: 47966
Li, H. T., Du, H. N., Tang, L., Hu, J. & Hu, H. Y. Structural transformation and aggregation of human α-synuclein in trifluoroethanol: non-amyloid component sequence is essential and β-sheet formation is prerequisite to aggregation. Biopolymers 64, 221–226 (2002).
pubmed: 12115139 doi: 10.1002/bip.10179
Crowther, R. A., Jakes, R., Spillantini, M. G. & Goedert, M. Synthetic filaments assembled from C-terminally truncated α-synuclein. FEBS Lett. 436, 309–312 (1998).
pubmed: 9801138 doi: 10.1016/S0014-5793(98)01146-6
Conway, K. A., Harper, J. D. & Lansbury, P. T. Jr. Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson’s disease are typical amyloid. Biochemistry 39, 2552–2563 (2000).
pubmed: 10704204 doi: 10.1021/bi991447r
Serpell, L. C., Berriman, J., Jakes, R., Goedert, M. & Crowther, R. A. Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross-β conformation. Proc. Natl Acad. Sci. USA 97, 4897–4902 (2000).
pubmed: 10781096 doi: 10.1073/pnas.97.9.4897 pmcid: 18329
Miake, H., Mizusawa, H., Iwatsubo, T. & Hasegawa, M. Biochemical characterization of the core structure of α-synuclein filaments. J. Biol. Chem. 277, 19213–19219 (2002).
pubmed: 11893734 doi: 10.1074/jbc.M110551200
Mougenot, A. L. et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol. Aging 33, 2225–2228 (2012).
pubmed: 21813214 doi: 10.1016/j.neurobiolaging.2011.06.022
Luk, K. C. et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949–953 (2012).
pubmed: 23161999 pmcid: 3552321 doi: 10.1126/science.1227157
Masuda-Suzukake, M. et al. Prion-like spreading of pathological α-synuclein in brain. Brain 136, 1128–1138 (2013).
pubmed: 23466394 pmcid: 3613715 doi: 10.1093/brain/awt037
Osterberg, V. R. et al. Progressive aggregation of α-synuclein and selective degeneration of Lewy inclusion-bearing neurons in a mouse model of parkinsonism. Cell Rep. 10, 1252–1260 (2015).
pubmed: 25732816 pmcid: 4351119 doi: 10.1016/j.celrep.2015.01.060
Peelaerts, W. et al. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522, 340–344 (2015).
pubmed: 26061766 doi: 10.1038/nature14547
Peng, C. et al. Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies. Nature 557, 558–563 (2018).
pubmed: 29743672 pmcid: 5970994 doi: 10.1038/s41586-018-0104-4
Prusiner, S. B. et al. Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc. Natl Acad. Sci. USA 112, E5308–E5317 (2015).
pubmed: 26324905 doi: 10.1073/pnas.1514475112 pmcid: 4586853
Tarutani, A., Arai, T., Murayama, S., Hisanaga, S. I. & Hasegawa, M. Potent prion-like behaviors of pathogenic α-synuclein and evaluation of inactivation methods. Acta Neuropathol. Commun. 6, 29 (2018).
pubmed: 29669601 pmcid: 5907316 doi: 10.1186/s40478-018-0532-2
Yamasaki, T. R. et al. Parkinson’s disease and multiple system atrophy have distinct α-synuclein seed characteristics. J. Biol. Chem. 294, 1045–1058 (2019).
pubmed: 30478174 doi: 10.1074/jbc.RA118.004471
Lavenir, I. et al. Silver staining (Campbell–Switzer) of neuronal α-synuclein assemblies induced by multiple system atrophy and Parkinson’s disease brain extracts in transgenic mice. Acta Neuropathol. Commun. 7, 148 (2019).
pubmed: 31522685 pmcid: 6745790 doi: 10.1186/s40478-019-0804-5
Klingstedt, T. et al. Luminescent conjugated oligothiophenes distinguish between α-synuclein assemblies of Parkinson’s disease and multiple system atrophy. Acta Neuropathol. Commun. 7, 193 (2019).
pubmed: 31796099 pmcid: 6892142 doi: 10.1186/s40478-019-0840-1
Strohäker, T. et al. Structural heterogeneity of α-synuclein fibrils amplified from patient brain extracts. Nat. Commun. 10, 5535 (2019).
pubmed: 31797870 pmcid: 6893031 doi: 10.1038/s41467-019-13564-w
Shahnawaz, M. et al. Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature 578, 273–277 (2020).
pubmed: 32025029 pmcid: 7066875 doi: 10.1038/s41586-020-1984-7
Campbell, B. C. V. et al. The solubility of α-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson’s disease. J. Neurochem. 76, 87–96 (2001).
pubmed: 11145981 doi: 10.1046/j.1471-4159.2001.00021.x
Fujiwara, H. et al. α-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160–164 (2002).
pubmed: 11813001 doi: 10.1038/ncb748
Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. & Goedert, M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc. Natl Acad. Sci. USA 95, 6469–6473 (1998).
pubmed: 9600990 doi: 10.1073/pnas.95.11.6469 pmcid: 27806
Tuttle, M. D. et al. Solid-state NMR structure of a pathogenic fibril of full-length human α-synuclein. Nat. Struct. Mol. Biol. 23, 409–415 (2016).
pubmed: 27018801 pmcid: 5034296 doi: 10.1038/nsmb.3194
Guerrero-Ferreira, R. et al. Cryo-EM structure of alpha-synuclein fibrils. eLife 7, e36402 (2018).
pubmed: 29969391 pmcid: 6092118 doi: 10.7554/eLife.36402
Li, Y. et al. Amyloid fibril structure of α-synuclein determined by cryo-electron microscopy. Cell Res. 28, 897–903 (2018).
pubmed: 30065316 pmcid: 6123497 doi: 10.1038/s41422-018-0075-x
Li, B. et al. Cryo-EM of full-length α-synuclein reveals fibril polymorphs with a common structural kernel. Nat. Commun. 9, 3609 (2018).
pubmed: 30190461 pmcid: 6127345 doi: 10.1038/s41467-018-05971-2
Guerrero-Ferreira, R. et al. Two new polymorphic structures of human full-length alpha-synuclein fibrils solved by cryo-electron microscopy. eLife 8, e48907 (2019).
pubmed: 31815671 pmcid: 6957273 doi: 10.7554/eLife.48907
Boyer, D. R. et al. Structures of fibrils formed by α-synuclein hereditary disease mutant H50Q reveal new polymorphs. Nat. Struct. Mol. Biol. 26, 1044–1052 (2019).
pubmed: 31695184 pmcid: 6907165 doi: 10.1038/s41594-019-0322-y
Boyer, D. R. et al. The α-synuclein hereditary mutation E46K unlocks a more stable, pathogenic fibril structure. Proc. Natl Acad. Sci. USA 117, 3592–3602 (2020).
pubmed: 32015135 doi: 10.1073/pnas.1917914117 pmcid: 7035510
Zhao, K. et al. Parkinson’s disease associated mutation E46K of α-synuclein triggers the formation of a novel fibril structure. Preprint at https://www.biorxiv.org/content/10.1101/870758v2 .
Sangwan, S. et al. Inhibition of synucleinopathic seeding by rationally designed inhibitors. eLife 9, e46775 (2020).
pubmed: 31895037 pmcid: 6977966 doi: 10.7554/eLife.46775
Goedert, M., Falcon, B., Zhang, W., Ghetti, B. & Scheres, S. H. W. Distinct conformers of assembled tau in Alzheimer’s and Pick’s diseases. Cold Spring Harb. Symp. Quant. Biol. 83, 163–171 (2018).
pubmed: 30886056 doi: 10.1101/sqb.2018.83.037580
Goedert, M., Spillantini, M. G., Cairns, N. J. & Crowther, R. A. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 8, 159–168 (1992).
pubmed: 1530909 doi: 10.1016/0896-6273(92)90117-V
Giasson, B. I. et al. A panel of epitope-specific antibodies detects protein domains distributed throughout human α-synuclein in Lewy bodies of Parkinson’s disease. J. Neurosci. Res. 59, 528–533 (2000).
pubmed: 10679792 doi: 10.1002/(SICI)1097-4547(20000215)59:4<528::AID-JNR8>3.0.CO;2-0
Spina, S. et al. The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family. Brain 131, 72–89 (2008).
pubmed: 18065436 doi: 10.1093/brain/awm280
Nonaka, T., Watanabe, S. T., Iwatsubo, T. & Hasegawa, M. Seeded aggregation and toxicity of α-synuclein and tau: cellular models of neurodegenerative diseases. J. Biol. Chem. 285, 34885–34898 (2010).
pubmed: 20805224 pmcid: 2966103 doi: 10.1074/jbc.M110.148460
Tarutani, A. et al. The effect of fragmented pathogenic α-synuclein seeds on prion-like propagation. J. Biol. Chem. 291, 18675–18688 (2016).
pubmed: 27382062 pmcid: 5009244 doi: 10.1074/jbc.M116.734707
Kametani, F. et al. Mass spectrometric analysis of accumulated TDP-43 in amyotrophic lateral sclerosis brains. Sci. Rep. 6, 23281 (2016).
pubmed: 26980269 pmcid: 4793195 doi: 10.1038/srep23281
Zivanov, J. et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. eLife 7, e42166 (2018).
pubmed: 30412051 pmcid: 6250425 doi: 10.7554/eLife.42166
Rohou, A. & Grigorieff, N. CTFFIND4: fast and accurate defocus estimation from electron micrographs. J. Struct. Biol. 192, 216–221 (2015).
pubmed: 26278980 pmcid: 6760662 doi: 10.1016/j.jsb.2015.08.008
He, S. & Scheres, S. H. W. Helical reconstruction in RELION. J. Struct. Biol. 198, 163–176 (2017).
pubmed: 28193500 pmcid: 5479445 doi: 10.1016/j.jsb.2017.02.003
Scheres, S. H. W. Amyloid structure determination in RELION-3.1. Acta Crystallogr. D. 76, 94–101 (2020).
doi: 10.1107/S2059798319016577
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486–501 (2010).
pubmed: 20383002 pmcid: 2852313
Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D 66, 213–221 (2010).
pubmed: 20124702 doi: 10.1107/S0907444909052925 pmcid: 2815670
Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D 66, 12–21 (2010).
doi: 10.1107/S0907444909042073 pubmed: 20057044

Auteurs

Manuel Schweighauser (M)

MRC Laboratory of Molecular Biology, Cambridge, UK.

Yang Shi (Y)

MRC Laboratory of Molecular Biology, Cambridge, UK.

Airi Tarutani (A)

Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.

Fuyuki Kametani (F)

Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.

Alexey G Murzin (AG)

MRC Laboratory of Molecular Biology, Cambridge, UK.

Bernardino Ghetti (B)

Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.

Tomoyasu Matsubara (T)

Department of Neuropathology, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.

Taisuke Tomita (T)

Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.

Takashi Ando (T)

Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Kazuko Hasegawa (K)

Division of Neurology, Sagamihara National Hospital, Sagamihara, Japan.

Shigeo Murayama (S)

Department of Neuropathology, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.

Mari Yoshida (M)

Institute for Medical Science of Aging, Aichi Medical University, Nagakute, Japan.

Masato Hasegawa (M)

Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.

Sjors H W Scheres (SHW)

MRC Laboratory of Molecular Biology, Cambridge, UK. scheres@mrc-lmb.cam.ac.uk.

Michel Goedert (M)

MRC Laboratory of Molecular Biology, Cambridge, UK. mg@mrc-lmb.cam.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH